Chief investigator Professor Alan Burnett, from Cardiff Universitys School of Medicine, commented on the findings:
These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects.
Although there has been some controversy around the use of GO following its withdrawal in the US two years ago, these results appear extremely promising and suggest no such cause for concern if the appropriate dose is given. Crucially, this represents some of the first progress in treating AML patients of this age group for at least 20 years.
More top news
He suggested people who are not concerned about the new notes donate their bodies for 'decorative use in future five pound notes'.
Tens of thousands of people lined the streets of Chapecó for a memorial ceremony honouring footballers killed in a plane crash.
Drivers with remote locking vehicles are being advised to manually check their cars are locked before leaving them.